Indaptus Therapeutics Stock (NASDAQ: INDP)

Indaptus Therapeutics (NASDAQ:INDP) Stock, Quote.Headers.trade-ideas

Indaptus Therapeutics

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

INDP

Biotech

News

Health Care

Market-Moving Exclusives

Exclusives

General

Indaptus advanced its Decoy20 trial to test a combination with tislelizumab, aiming to enhance checkpoint inhibitor effectiveness in cancer treatment.

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene&#39;s Cancer Drug For Advanced Solid Tumors

Screenshot 2025-03-17 at 5.34.34 PM

Aggressive Cancers In Young People Are On The Rise – Can The Immune System Fight Back Better? Indaptus Therapeutics Thinks So

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AGFY

AMRN

ARRY

AUMN

BBWI

BCAN

BEDU

BFLY

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLUE

CMPS

COMM

CRML

CSTL

CTKB

DAVA

DUOL

ENVB

ESTA

FIGS

GRFS

GYRE

HAYW

IHRT

INSG

IONQ

IRWD

LPSN

MGNI

MIST

MRSN

NARI

NTES

NWTN

OCEA

OKTA

ORIC

PSTG

PZZA

QURE

RNLX

RVNC

SCTL

SDGR

SHLS

SIDU

SNOW

STER

STKL

SWIM

TASK

VERX

VLCN

XMTR

Shares of  Butterfly Network, Inc.  (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics Inc

Press Releases

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Legal

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Registration Is Now Open For Tribe Public's Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Earnings

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Analyst Ratings

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AIM ImmunoTech

Ainos

Alzamend Neuro

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aprea Therapeutics

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Ernexa Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

Immuron Limited - American Depositary Shares

Immuron

Mainz Biomed

Ocean Biomedical

PharmaCyte Biotech

Portage Biotech

Plus Therapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

Maxim Group

HC Wainwright & Co.

Comments

Indaptus Therapeutics

Indaptus Therapeutics (NASDAQ:INDP) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga